Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 1, 2009, Pages 24-29

  He, Shu ^a,c   Bark, Niklas ^b   Wang, Haiyao ^b   Svensson, Jan ^b   Blombäck, Margareta ^a,b  

^a Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ASA; Fibrin fiber thickness; Fibrin gel porosity; Fibrinolysis

Indexed keywords

ACETYLSALICYLIC ACID; FIBRIN; FIBRINOGEN; PLASMIN; SALICYLIC ACID; THROMBIN; GEL;

ACETYLATION; ARTICLE; BLOOD ANALYSIS; CONFOCAL MICROSCOPY; FIBRINOLYSIS; PERMEABILITY; POROSITY; PRIORITY JOURNAL; PROTEIN PURIFICATION; THICKNESS; UPREGULATION; BLOOD CLOTTING; BLOOD CLOTTING TEST; CHEMISTRY; DRUG EFFECTS; GEL; HUMAN; METABOLISM; PHARMACOLOGY; PHYSIOLOGY; THROMBOCYTE;

ASPIRIN; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PLATELETS; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; GELS; HUMANS; PERMEABILITY; POROSITY; SALICYLIC ACID; THROMBIN; UP-REGULATION;

EID: 67651093879     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181953e0f     Document Type: Article

References (28)

1. Collet JP, Soria J, Mirshahi M, et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood. 1993;82:2462-2469. (Pubitemid 23304270)
2. Collet JP, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol. 2000; 20:1354-1361. (Pubitemid 30262939)
3. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem. 1992;267:24259-24263.
4. Blombäck B, Carlsson K, Fatah K, et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res. 1994;75:521-538. (Pubitemid 24267336)
5. He S, Cao H, Antovic A, et al. Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. Blood Coagul Fibrinolysis. 2005;16:61-67.
6. Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol. 2008;28:25-32.
7. Antithrombotic tralists's Collaboration. Collaborative meta-analysis of randomized trial of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
8. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. 2002;162:2197-2202.
9. Roth GJ, Siok CJ. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975;56:624-632.
10. Loew D, Vinazzer H. Dose-dependent influence of acetylsalicylic acid on platelet functions and plasmatic coagulation factors. Haemostasis. 1976; 5:239-249.
11. Fatah K, Beving H, Albåge A, et al. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J. 1996;17:1362-1366.
12. Williams S, Fatah K, Hjemdahl P, et al. Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J. 1998;19:1666-1672. (Pubitemid 28524185)
13. Pinckard RN, Hawkins D, Farr RS. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature. 1968;219:68-69.
14. Undas A, Sydor WJ, Brummel K, et al. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation. 2003;107: 17-20. (Pubitemid 36070925)
15. Blombäck B, Carlsson K, Hessel B, et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta. 1989;997:96-110. (Pubitemid 19178601)
16. Wolberg AS, Gabriel DA, Hoffman M. Analyzing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis. 2002;13: 533-539.
17. von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood. 1995;86:3035-3042.
18. Blombäck B, Banerjee D, Carlsson K, et al. Native fibrin gel networks and factors influencing their formation in health and disease. Adv Exp Med Biol. 1990;281:1-23.
19. Thiessen JJ. Aspirin: plasma concentration and effects. Thromb Res. 1983; 4:105-111.
20. Dahl ML, Puustinen T, Uotila P. Sodium salicylate interferes with the inhibitory effects of aspirin and indomethacin on human platelets. Prostaglandins Leukot Med. 1983;12:21-28.
21. Ariëns RA, Philippou H, Nagaswami C, et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000;96:988-995. (Pubitemid 30616865)
22. Williams S, Fatah K, Ivert T, et al. The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis. 1995;8:718-725. (Pubitemid 26047201)
23. He S, Blombäck M, Yoo G, et al. Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system. Ann N Y Acad Sci. 2001;936:531-535. (Pubitemid 32613938)
24. Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther. 1989;250: 154-161.
25. Benedek IH, Joshi AS, Pieniaszek HJ, et al. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol. 1995;35:1181-1186. (Pubitemid 26020040)
26. Zhang CL, Wilson KM, Stafford I, et al. Absorption kinetics of low dose aspirin in patients with evolving acute myocardial infarction. Drug Invest. 1994;7:169-174. (Pubitemid 24126252)
27. Brantmark B, Hedner U, Melander A, et al. Salicylate inhibition of antiplatelet effect of aspirin. Lancet. 1981;2:1349-11349 (Pubitemid 12180409)
28. Dejana E, Cerletti C, de Castellarnau C, et al. Salicylate-aspirin interaction in the rat. Evidence that salicylate accumulating during aspirin administration may protect vascular prostacyclin from aspirin-induced inhibition. J Clin Invest. 1981;68:1108-1112. (Pubitemid 11023542)